Here’s what you should know:
1. Goldman Sachs cited balance sheet concerns, litigation risks and competition-related pressure as the reason behind the rating.
2. Valeant opened the week at $21.36 Jan. 22, and it was trading at $19.83 as of 1:30 p.m. EST Jan. 24.
3. Valeant hit a 14-month high of $24.45 Jan. 5, but has now dropped below its 10-and 20-day moving averages.
More articles on supply chain:
Congress suspends medical device tax through stopgap spending deal — 6 insights
Cowen: Amazon could leverage Alexa to invade healthcare space
FDA grants IlluminOss marketing clearance for bone stabilization system
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.